Regeneron Pharmaceuticals (REGN) Stock Insights

REGN$951.19—
BiotechnologyLarge CapHigh Quality
Compare
Market cap$95.23BEnterprise value—Revenue (TTM)$16.9BMarket positionTop 25%

Score

57
Neutral
Value
50
Quality
70
Growth
52

Insights

  • Revenue by product
  • Revenue by region
Revenue by product
PeriodValue
FY2012Arcalyst Net Product Sales: 20200000.0, EYLEA Net Product Sales: 837900000.0
FY2013Aflibercept Agreement: -15489000.0, Antibody Collaboration: 445600000.0
FY2014Aflibercept Agreement: 5193000.0, Antibody Collaboration: 536106000.0
FY2015Aflibercept Agreement: 15922000.0, Antibody Collaboration: 662990000.0, Immuno-oncology Agreement: 79961000.0, IO Agreement: 640000000.0
FY2016Aflibercept Agreement: 26200000.0, Antibody Collaboration: 440168000.0, Immuno-oncology Agreement: 218497000.0, IO Agreement: 640000000.0
FY2017Aflibercept Agreement: 24800000.0, Antibody Collaboration: 553689000.0, Immuno-oncology Agreement: 323504000.0
FY2018Product: 4106200000.0
FY2019Product: 4834400000.0
FY2020Product: 5567600000.0
FY2021Product: 12117200000.0, Product and Service, Other: 281200000.0
FY2022Collaboration Revenue: 2058400000.0, Product: 6893700000.0, Product and Service, Other: 365100000.0
FY2023Collaboration Revenue: 5503100000.0, Product: 7078000000.0, Product and Service, Other: 536100000.0
FY2024Collaboration Revenue: 6057800000.0, Product: 7629200000.0, Product and Service, Other: 515000000.0
FY2025Collaboration Revenue: 7331200000.0, Product: 6309100000.0, Product and Service, Other: 702600000.0
Revenue by region
PeriodValue
FY2025Rest Of World: 507500000.0, UNITED STATES: 4384700000.0

Regeneron Pharmaceuticals (REGN) Stock Insights

REGN price $951.19 —

Ticker
REGN
Price
$951.19
Change
—
Market cap
$95.23B
P/E
19.82
Forward P/E
11.49
Dividend yield
0.39%
Beta
0.24
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
57
Value
50
Quality
70
Growth
52

Stocklytics score rationale: value 50, quality 70, growth 52.

AI Score 85. Regeneron Pharmaceuticals, Inc. has a strong market cap of approximately $95.5 billion and impressive profit margins, with a net profit margin of 28.5%

Insights

Revenue by product
PeriodValue
FY2012Arcalyst Net Product Sales: 20200000.0, EYLEA Net Product Sales: 837900000.0
FY2013Aflibercept Agreement: -15489000.0, Antibody Collaboration: 445600000.0
FY2014Aflibercept Agreement: 5193000.0, Antibody Collaboration: 536106000.0
FY2015Aflibercept Agreement: 15922000.0, Antibody Collaboration: 662990000.0, Immuno-oncology Agreement: 79961000.0, IO Agreement: 640000000.0
FY2016Aflibercept Agreement: 26200000.0, Antibody Collaboration: 440168000.0, Immuno-oncology Agreement: 218497000.0, IO Agreement: 640000000.0
FY2017Aflibercept Agreement: 24800000.0, Antibody Collaboration: 553689000.0, Immuno-oncology Agreement: 323504000.0
FY2018Product: 4106200000.0
FY2019Product: 4834400000.0
FY2020Product: 5567600000.0
FY2021Product: 12117200000.0, Product and Service, Other: 281200000.0
FY2022Collaboration Revenue: 2058400000.0, Product: 6893700000.0, Product and Service, Other: 365100000.0
FY2023Collaboration Revenue: 5503100000.0, Product: 7078000000.0, Product and Service, Other: 536100000.0
FY2024Collaboration Revenue: 6057800000.0, Product: 7629200000.0, Product and Service, Other: 515000000.0
FY2025Collaboration Revenue: 7331200000.0, Product: 6309100000.0, Product and Service, Other: 702600000.0
Revenue by region
PeriodValue
FY2025Rest Of World: 507500000.0, UNITED STATES: 4384700000.0

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener